Physician profile
Gary Eliot Fink
NPI 1699873885
$2,857,826.01
in general payments reported to CMS, 2019-2025
29 companies · $1.0M in 2025
The $1.0M reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,717 · 2020: $101K · 2021: $205K · 2022: $456K · 2023: $636K · 2024: $433K · 2025: $1.0M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1.4M · Royalty Or License: $624K · Grant: $23K · Food and Beverage: $1,051 · Travel and Lodging: $632 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,445,146.53 |
| Royalty Or License | $624,221.41 |
| Grant | $22,584.00 |
| Food and Beverage | $1,051.06 |
| Travel and Lodging | $631.95 |
| Education | $120.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| American Rheumatology Network, LLC | $2,819,607.01 | 2020-2025 | |
| Abbvie INC. | $32,148.39 | 2019-2025 | |
| Janssen Biotech, INC. | $1,356.63 | 2019-2023 | Tremfya, Simponi Aria |
| Amgen INC. | $704.34 | 2019-2023 | Otezla, Enbrel, Amjevita |
| Ucb, INC. | $452.21 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $424.88 | 2019-2023 | Orencia |
| Novartis Pharmaceuticals Corporation | $380.17 | 2019-2022 | |
| Octapharma USA, INC. | $331.23 | 2022 | |
| Glaxosmithkline, LLC. | $315.10 | 2019-2023 | Benlysta |
| Pfizer INC. | $309.67 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $295.70 | 2019-2022 | |
| Horizon Therapeutics Plc | $190.00 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $166.94 | 2021-2023 | Evusheld |
| Aurinia Pharma U.S., INC. | $146.42 | 2022-2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.08 | 2019-2023 | Ofev |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $128.24 | 2019-2021 | |
| Genentech USA, INC. | $125.00 | 2019-2021 | |
| Lilly USA, LLC | $109.49 | 2019-2022 | |
| Biogen, INC. | $102.62 | 2019 | |
| Merck Sharp & Dohme LLC | $79.14 | 2019-2021 | |
| Organon LLC | $76.79 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $57.92 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $47.70 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $31.17 | 2020 | |
| Boston Scientific Corporation | $30.11 | 2022 | |
| Depuy Synthes Sales INC. | $24.10 | 2020 | |
| Fresenius Kabi USA, LLC | $21.54 | 2023 | |
| Alexion Pharmaceuticals, INC. | $17.15 | 2021 | |
| Genzyme Corporation | $16.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,557,985.08 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Fink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.